Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Conestoga Mid Cap Composite 2023 Q2 Investor Letter | Buyside Digest

Back to Fund Profile (Conestoga Mid Cap Composite)

Primary Source Intelligence • Q2 2023 Letter Analysis

Conestoga Mid Cap Composite Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Conestoga Mid Cap Composite. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+8.7%

YTD+19.82%

Annualized+12.09%

Positioning StanceConstructive

Market CapMid Cap

GeographyUS

Digest Analysis

Quick Take

"Conestoga's Mid Cap strategy outperformed in Q2 2023 with an 8.70% return, driven by strong stock selection in Consumer Discretionary and Health Care. Technology holdings showed mixed results while biotech-related positions faced industry headwinds."

Executive Summary

Conestoga's Mid Cap Composite delivered strong performance in Q2 2023, returning 8.70% net versus the Russell Mid Cap Growth Index's 6.23%. Year-to-date performance reached 19.82% versus the benchmark's 15.94%. The strategy benefited from positive stock selection in Consumer Discretionary and Health Care sectors, with standout performers including CoStar Group, Copart, Verisk Analytics, and Rollins. These companies demonstrated resilient business models and strong execution despite challenging market conditions. Technology sector performance was mixed, with software positions showing varied results due to implementation complexities and elongated sales cycles. The portfolio faced headwinds from biotech-related holdings experiencing industry-wide inventory destocking and spending restraint. However, management maintains conviction in these positions, expecting improvement in 2024. The strategy continues to focus on high-quality companies with sustainable growth characteristics and strong balance sheets, employing a patient, long-term approach that has resulted in consistent outperformance since the current management team took over in late 2020.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

72%

CautiousHigh

High Conviction (72%)

The strategy demonstrates high conviction through concentrated holdings (30-45 positions), detailed individual stock analysis, and willingness to maintain positions through temporary headwinds. The managers provide specific reasoning for each holding and express confidence in long-term prospects despite near-term challenges.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The manager acknowledges challenging market conditions including macroeconomic uncertainty and sector-specific headwinds, but maintains a constructive view on their holdings' long-term prospects. They note that management teams are wisely deploying conservative strategies during uncertainty.

Risk Appetite

15%

DefensiveAggressive

Defensive (15%)

The portfolio maintains positions in companies facing temporary headwinds, showing selective risk-taking. Management emphasizes conservative approaches and preserving margins during uncertain times, indicating a cautious but not defensive positioning.

Capital Deployment

5%

De-riskingDeploying

De-risking (5%)

The document shows minimal net deployment activity with only position additions and trims mentioned but no new purchases or sales. The strategy appears to be maintaining current positioning rather than making significant capital allocation changes.

Forward Guidance

30%

CautiousExpansionary

Cautious (30%)

The manager expresses confidence that challenged sectors will improve in 2024 and believes current management teams are well-positioned for when conditions improve. This shows a moderately positive deployment bias for the future.

Language Signal

20%

BearishBullish

Bearish (20%)

Language is balanced with mentions of both challenges (headwinds, uncertainty, pressured) and opportunities (solid results, strong execution, resilient business models). The tone is professional and measured rather than overtly bullish or bearish.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

The manager acknowledges multiple risk factors including macroeconomic uncertainty, biotech industry challenges, and supply chain constraints. However, these are discussed as manageable headwinds rather than systemic threats, indicating moderate risk perception.

Opportunity Density

60%

ScarceAbundant

Selective (60%)

The manager identifies selective opportunities within their existing holdings and expresses confidence in companies' ability to navigate current challenges. They see improving conditions ahead in 2024, suggesting a moderately rich opportunity set within their focus areas.

Time Horizon

75%

Short-TermLong-Term

Decade+ (75%)

The strategy explicitly emphasizes a patient, long-term approach with low turnover rates of 20-30%. The manager maintains positions through temporary headwinds expecting improvement in 2024 and beyond, demonstrating a multi-year investment horizon with willingness to hold through volatility.